Urea
Formulations: - Local > Topical > Cream: 10%; 5% Local > Topical > Ointment: 10%; 5% - Local > Topical > Cream: 5 per % Indications: - Xerosis cutis or asteatosis - Atopic eczema Source: EML workbook import
MOQ: 1
Price on request
New Arrivals
Fresh additions to the Afya Chain catalogue, ready for discovery and procurement.
New Arrivals (Showing 564 out of 662)
Ustekinumab
Formulations: - Parenteral > General injections > SC: 45 mg per 0.5 mL in vial; 45 mg per 0.5 mL in pre-filled syringe; 45 mg per 0.5 mL in pre-filled pen; 90 mg per mL in pre-filled syringe; 90 mg per mL in pre-filled pen Indications: - Psoriasis of unspecified type Source: EML workbook import
MOQ: 1
Price on request
Amikacin
Indications: - Other specified conjunctivitis - Infectious blepharitis Source: EML workbook import
MOQ: 1
Price on request
Amoxicillin
Formulations: - Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate) Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate) - Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection Oral > Solid > dispersible tablet: 250 mg (scored) (as trihydrate); 500 mg (scored) (as trihydrate) Oral > Solid > dosage form: 250 mg (as trihydrate); 500 mg (as trihydrate) Indications: - Acute pharyngitis - Periapical abscess without sinus - Acute sinusitis - Acute otitis media - Chronic obstructive pulmonary disease with acute exacerbation - Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) - Bacterial pneumonia (Community-acquired pneumonia - severe) [children] - Sepsis without septic shock - Acute malnutrition in infants, children or adolescents (uncomplicated) [children] - Acute malnutrition in infants, children or adolescents (complicated) [children] - Bacterial meningitis - Bacterial infection of unspecified site - Infectious cystitis Alternatives: - gentamicin Source: EML workbook import
MOQ: 1
Price on request
Amoxicillin + Clavulanic Acid
Formulations: - Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt) - Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt) Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt) Indications: - Bacterial pneumonia (Community-acquired pneumonia - severe) [children] - Infectious cystitis - Neutropenia (low-risk) - Other specified pneumonia (Hospital-acquired pneumonia) - Bacterial cellulitis, erysipelas or lymphangitis - Peritonitis (mild-moderate) - Acute sinusitis - Peritoneal abscess (mild-moderate) - Chronic obstructive pulmonary disease with acute exacerbation - Bacterial pneumonia (Community-acquired pneumonia - mild to moderate) - Bacterial pneumonia (Community-acquired pneumonia - severe) - Bacterial infection of joint - Other specified prophylactic measures - Osteomyelitis or osteitis - Acute otitis media - Bacterial infection of unspecified site - Multi-drug resistant Mycobacterium tuberculosis Source: EML workbook import
MOQ: 1
Price on request
Ampicillin
Formulations: - Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous) - Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection Indications: - Bacterial pneumonia (Community-acquired pneumonia - severe) [children] - Acute malnutrition in infants, children or adolescents (complicated) [children] - Peritonitis (mild-moderate) - Peritonitis (severe) - Peritoneal abscess (mild-moderate) - Peritoneal abscess (severe) - Sepsis without septic shock - Bacterial meningitis - Bacterial infection of unspecified site Alternatives: - gentamicin Source: EML workbook import
MOQ: 1
Price on request
Benzathine Benzylpenicillin
Formulations: - Parenteral > General injections > IM: 1.2 million IU in vial (≈ 900 mg) powder for injection; 2.4 million IU in vial (≈ 1.8 g) powder for injection Indications: - Congenital syphilis [children] - Syphilis - Bacterial infection of unspecified site Source: EML workbook import
MOQ: 1
Price on request
Benzylpenicillin
Formulations: - Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt) Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt) - Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt) Indications: - Bacterial pneumonia (Community-acquired pneumonia - severe) [children] - Congenital syphilis [children] - Syphilis - Acute malnutrition in infants, children or adolescents (complicated) [children] - Sepsis without septic shock - Bacterial meningitis - Bacterial infection of unspecified site Alternatives: - gentamicin Source: EML workbook import
MOQ: 1
Price on request
Cefalexin
Formulations: - Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid Oral > Solid: 250 mg (as monohydrate) Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate) Oral > Solid > dispersible tablet: 125 mg; 250 mg Indications: - Bacterial cellulitis, erysipelas or lymphangitis - Chronic obstructive pulmonary disease with acute exacerbation - Acute pharyngitis - Bacterial infection of unspecified site Source: EML workbook import
MOQ: 1
Price on request
Cefazolin
Formulations: - Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection Indications: - Other specified prophylactic measures - Bacterial infection of joint - Osteomyelitis or osteitis - Surgical site infection Source: EML workbook import
MOQ: 1
Price on request
Chloramphenicol
Formulations: - Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection Oral > Liquid: 150 mg per 5 mL (as palmitate) Oral > Solid: 250 mg capsule - Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate) Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection Indications: - Bacterial meningitis - Bacterial infection of unspecified site Source: EML workbook import
MOQ: 1
Price on request
Clindamycin
Formulations: - Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride) Oral > Solid: 150 mg (as hydrochloride) capsule Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate) Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) Oral > Solid: 150 mg (as hydrochloride) Indications: - Necrotising fasciitis - Bacterial infection of joint - Osteomyelitis or osteitis - Bacterial infection of unspecified site Source: EML workbook import
MOQ: 1
Price on request
Sign Up to Our Newsletter→
Ready to amplify your rewards? Drop your email and we'll be in touch soon.